Cinnovir (PPF) inactivates broad spectrum of viruses
Pre-clinical studies have determined that PPF inactivates:
- Orthomyxoviridea – Influenza types H1N1, H9N2, H5N1, H5N3
- Paramyxoviridea – Parainfluenza, Newcastle disease
- Herpesviridea – Herpes Simplex 1, Herpes Simplex 2
- Retroviridea – HIV
- SARS-CoV-2
Safety
- Cinnovir is a natural water extract derived from cinnamon cassia (Cinnamomum cassia) solely by physical separation, utilizing no chemicals or solvents.
- Ground cinnamon is GRAS-confirmed and has been used for centuries in food preparation. (https://reference.medscape.com/drug/cinnamon-batavia-cassia-344478)
- 300 mg of Cinnovir is derived from 10 grams of ground cinnamon.
- There is some concern related to high intake of Cinnamomum cassia due to one of its constituents, coumarin, which if consumed in high doses can cause liver damage.
- This concern is irrelevant in our case since Novid-20 products are virtually coumarin-free.
anchor
SARS-CoV-2 Study
- The binding capacity of the lentivirus is about 200 times greater than that of SARS-CoV-2.
- The study found that rates of infection with the lentivirus decreased by approximately 60% after treatment with PPF, indicating that PPF may be effective in blocking SARS-CoV-2 and potentially other viruses as well. A lab study has been conducted (2021, Hebrew University) on PPF, examining potential antiviral activity of PPF by changes of the Spike-hACE2 interactions, using Spike-pseudotyped lentivirus.
- Additional data from this study is available upon request.
